These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19911123)

  • 21. Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma.
    Lin CC; Pu YS; Hsu CH; Keng HY; Cheng AL; Yang CH
    Urol Oncol; 2008; 26(6):659-61. PubMed ID: 18555710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
    Gao C; Hu S; Guo M; Hai X; Zhou J
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
    Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer.
    Hsueh YM; Chiou HY; Huang YL; Wu WL; Huang CC; Yang MH; Lue LC; Chen GS; Chen CJ
    Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):589-96. PubMed ID: 9264271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distributions and chemical forms of arsenic after intravenous administration of dimethylarsinic and monomethylarsonic acids to rats.
    Suzuki KT; Katagiri A; Sakuma Y; Ogra Y; Ohmichi M
    Toxicol Appl Pharmacol; 2004 Aug; 198(3):336-44. PubMed ID: 15276413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
    Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds.
    Hirano S; Kobayashi Y; Cui X; Kanno S; Hayakawa T; Shraim A
    Toxicol Appl Pharmacol; 2004 Aug; 198(3):458-67. PubMed ID: 15276427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study.
    Huang YK; Huang YL; Hsueh YM; Yang MH; Wu MM; Chen SY; Hsu LI; Chen CJ
    Cancer Causes Control; 2008 Oct; 19(8):829-39. PubMed ID: 18351295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
    Beer TM; Tangen CM; Nichols CR; Margolin KA; Dreicer R; Stephenson WT; Quinn DI; Raghavan D; Crawford ED
    Cancer; 2006 Jun; 106(12):2624-9. PubMed ID: 16688776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
    Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
    Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
    O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Westervelt P; Brown RA; Adkins DR; Khoury H; Curtin P; Hurd D; Luger SM; Ma MK; Ley TJ; DiPersio JF
    Blood; 2001 Jul; 98(2):266-71. PubMed ID: 11435292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arsenic trioxide: safety issues and their management.
    Au WY; Kwong YL
    Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
    Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
    Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arsenic species excretion after dimercaptopropanesulfonic acid (DMPS) treatment of an acute arsenic trioxide poisoning.
    Heinrich-Ramm R; Schaller H; Horn J; Angerer J
    Arch Toxicol; 2003 Feb; 77(2):63-8. PubMed ID: 12590357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.